Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 15 May
    2018

    Diurnal announces the launch of Alkindi® for the treatment of paediatric adrenal insufficiency in Germany

    First Diurnal product to be commercialised

    Read More

  • 20 Mar
    2018

    Placing update

    The Company has received a letter of notice to exercise the Broker Option in respect of 263,157 Option Shares

    Read More

  • 14 Mar
    2018

    Proposed Placing to raise up to £11 million, including Broker Option of up to £1 million and Notice of General Meeting

    Funds to be used to support the launch of Diurnal’s first approved product in Europe

    Read More